Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Share-based compensation expense

Asset impairment and restructuring costs

Expected credit losses on financial assets and related charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Canopy Growth

Canopy Growth Corp. engages in the production and sale of medical cannabis. The firm operates through the following segments: Global Cannabis and Other Consumer Products. The Global Cannabis segment encompasses the production, distribution and sale of a diverse range of cannabis and cannabinoid-based consumer products in Canada and internationally pursuant to applicable international and domestic legislation, regulations and permits. The Other Consumer Products segment encompasses the production, distribution and sale of consumer products by Storz & Bickel, This Works, BioSteel, and other ancillary revenue sources. It focuses on the treatment of chronic pain, seizures, muscle spasms, nausea, and loss of appetite. The company was founded by Bruce Linton on August 5, 2009 and is headquartered in Smith Falls, Canada.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Canopy Growth Corp. engages in the production, distribution, and sale of cannabis and cannabinoid-based products for both adult-use and medical purposes. The firm operates through the following segments: Canada Cannabis, Rest-of-world Cannabis, Storz and Bickel, BioSteel, This Works, and Other. The Canada Cannabis segment includes the production, distribution, and sale of cannabis, hemp, and cannabis products in Canada. The Rest-of-world Cannabis segment focuses on production and sale of cannabis, hemp, and cannabis products internationally. The Storz and Bickel segment produces and sells vaporizers. The BioSteel segment refers to the sale of consumer packaged goods including sports nutrition beverages, hydration mixes, proteins, and other specialty nutrition products. The This Works segment includes the production and sale of beauty, skincare, wellness, and sleep products, some of which have been blended with hemp-derived CBD isolate. The company was founded by Bruce Linton on August 5, 2009 and is headquartered in Smith Falls, Canada.

Canopy Growth recently reported earnings, so let's take a look at how the cannabis company and CGC stock look after the release.
The post How Canopy Growth Stock Looks After Fourth-Quarter Earnings appeared first on InvestorPlace.

How Canopy Growth Stock Looks After Fourth-Quarter Earnings

Canopy Growth CEO David Klein recently discussed the company’s strategy reset. If you own CGC stock, that’s not a bad thing.

Canopy Growth’s Strategy Reset Shouldn’t Be a Shock

Aurora Cannabis

Cronos Group

HEXO Corp

Tilray Brands

Cannabis stocks in general stumbled in the latter half of last year. Wall Street expects profits, and none of these companies is anywhere near profitability.

Short Sellers Hike Their Bets in Cannabis Stocks

Canopy Growth stock has been trading better lately, giving investors a glimpse of what CGC stock can do if it regains momentum.
The post Buy Canopy Growth Stock as Cannabis Again Enters the Spotlight appeared first on InvestorPlace.

Buy Canopy Growth Stock as Cannabis Again Enters the Spotlight

Their share prices are down, but their businesses remain strong.

3 Beaten-Down Marijuana Stocks That Are Stronger Than They Look

Aphria

OrganiGram Holdings Inc.

Could this be the next industry to rebound?

Why Aurora Cannabis, HEXO, Cronos Group, and Other Cannabis Stocks Surged Today

The devastation from the coronavirus spared very few sectors and marijuana wasn’t one of them. However, this has created a long-term catalyst for CGC stock that few are talking about.

Canopy Growth Has a Catalyst That Few Are Talking About

CGC stock faced selling pressure when the company acknowledged that its restructuring failed to lower its losses in the quarter.
The post Be Cautious When Buying Faltering Canopy Stock appeared first on InvestorPlace.

Be Cautious When Buying Faltering Canopy Stock

Green Thumb Industries Inc.

Two are flying high right now, but one isn't.

3 Top Marijuana Stocks to Watch in June 2020

The cannabis company's unimpressive fourth-quarter results might urge you to abandon on this stock. Should you?

Canopy Growth: Should You Give Up or Hold On?

Another loss isn't what investors should be worried about.

This Is the Biggest Problem in Canopy Growth's Q4 Earnings Report

Potential needle-movers remain in motion for CGC stock. But as shares may not reflect continued challenges, hold off buying for now.

Catalysts Remain in Play, but Canopy Growth Stock Remains a Hold for Now

While Canopy Growth Corp (NYSE: CGC) has announced strategic changes that could help lower its cost burden, the company is “sized for growth” that may not materialize in the medium-term, according to MKM Partners.

Canopy Growth Is Growing More Pot Than It Can Sell, MKM Says

Should investors be worried about this pot industry giant going out of business?

Is Canopy Growth at Risk of Going Bankrupt?

Constellation Brands

Visa

This trio of names is planning for what customers will want after the coronavirus pandemic abates.

3 Top Stocks to Buy in  June

MedMen Enterprises Inc.

These marijuana stocks are unlikely to have pot stock investors seeing green.

3 Cannabis Stocks to Avoid Like the Plague in June

Awful earnings and a subsequent drubbing don't mean Canopy Growth is down and out; there's still potential for CGC stock as a turnaround play.
The post If Canopy Reclaims $19 Price Level, CGC Stock Could Still Turn Around appeared first on InvestorPlace.

If Canopy Reclaims $19 Price Level, CGC Stock Could Still Turn Around

Aurora easily outperformed Canopy last month. But don't count Canopy out.

Why Canopy Growth Is Still a Better Marijuana Stock Than Aurora Cannabis

The marijuana stock rebound in 2020 has run into a brick wall, but the fundamentals supporting the industry continue to improve.
The post 4 Marijuana Stocks to Buy for the Big 2020 Rebound appeared first on InvestorPlace.

4 Marijuana Stocks to Buy for the Big 2020 Rebound

A formerly bullish analyst is now bearish on the popular cannabis company -- and he's warning that more pain could lie ahead for shareholders.

Should You Sell Canopy Growth Stock?

CGC stock jumped after research suggested cannabis could help prevent or treat Covid-19. This could boost cannabis legalization efforts.

Canopy Growth Shares Rally on Potential Benefit for Covid-19

The U.S.-listed shares of Canopy Growth Corp. CGC, -20.02% WEED, -20.80% dropped 4.2% in premarket trading Monday, after Stifel Nicolaus analyst Andrew Carter swung to bearish from bullish in the wake of the Canada-based cannabis company's disappointing earnings report and "significant" challenges ahead.

Canopy Growth's stock drops again after Stifel Nicolaus swings to bearish from bullish

Canopy Growth Corp: Something Has To Change

10 Things to Hate About Canopy Growth's Q4 Update

Facebook's Zuckerberg will leave up 'inflammatory' Trump post about Minnesota protests

News for Canopy Growth Stock (CGC)